The American pharmaceutical group Pfizer recorded sales of 25.7 billion dollars in the first quarter, an increase of 77% year-on-year, largely thanks to income from the sale of its vaccine against Covid-19 .
Soon a pill
The company has also maintained its forecast of selling $ 22 billion of its anti-Covid-19 pill, Paxlovid, over the whole year. On the other hand, it revised downwards its estimate of annual profit, mainly due to the change in accounting standards.
The World Health Organization (WHO) strongly recommended this antiviral in April for patients with less severe forms of Covid-19 and “at higher risk of hospitalization”.
Falling annual profit
Pfizer, on the other hand, revised its annual profit estimate downwards, mainly due to a change in its accounting standards. The American stock market regulator requires pharmaceutical groups to include certain expenses, in particular for acquisitions in research and development, in their financial projections.
Pfizer now expects annual earnings per share to be between $6.25 and $6.45, down from a range of $6.35 to $6.55 previously.